ERBB2 and breast carcinoma: One investigational hypothesis proposed by Nowsheen et al. mechanistically explains the susceptibility of HER2+ breast cancer cells to PARP inhibition is that HER2 activates the NF–kB signaling pathway, which has been shown to be dependent on PARP [11,12].